6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents

James L. Kelley, R Morris Bullock, Mark P. Krochmal, Ed W. McLean, James A. Linn, Micheal J. Durcan, Barrett R. Cooper

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A series of 6-(alkylamino)-9-alkylpurines was synthesized and evaluated for the property of antagonizing the behavioral effects in animals of the dopamine agonist apomorphine. This model for identifying potential antipsychotic agents is based on the hypothesis that agents that antagonize apomorphine-induced aggressive behavior in rats and apomorphine-induced climbing in mice, but that do not block stereotyped behavior, could have an antipsychotic effect in humans without producing extrapyramidal side effects. The antiaggressive-behavior activity of lead compound 1 (6-(dimethylamino)- 9-(3-phenylalaninamidobenzyl)-9H-purine) was improved 48-fold with 6- (cyclopropylamino)-9-(cyclopropylmethyl)-2-(trifluoromethyl)-9H-purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterative sequence of structure-activity relationship studies that encompassed evaluation of the effects of structure variations at the purine 9-, 6-, and 2-positions. Potency was enhanced with a 9-cyclopropyl group, the duration of action was improved with the 6-(cyclopropylamino) substituent, potency was further enhanced with an N-formyl prodrug, and an agent with reduced cardiovascular effect emerged with the 2-trifluoromethyl purine 80. This potential antipsychotic agent was not developed further due to undesirable effects on the stomach.

Original languageEnglish
Pages (from-to)3207-3216
Number of pages10
JournalJournal of Medicinal Chemistry
Volume40
Issue number20
DOIs
Publication statusPublished - 1997

Fingerprint

Antipsychotic Agents
Apomorphine
Stereotyped Behavior
Lead compounds
Dopamine Agonists
Prodrugs
Structure-Activity Relationship
Rats
Stomach
Animals
purine

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Kelley, J. L., Bullock, R. M., Krochmal, M. P., McLean, E. W., Linn, J. A., Durcan, M. J., & Cooper, B. R. (1997). 6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents. Journal of Medicinal Chemistry, 40(20), 3207-3216. https://doi.org/10.1021/jm960662s

6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents. / Kelley, James L.; Bullock, R Morris; Krochmal, Mark P.; McLean, Ed W.; Linn, James A.; Durcan, Micheal J.; Cooper, Barrett R.

In: Journal of Medicinal Chemistry, Vol. 40, No. 20, 1997, p. 3207-3216.

Research output: Contribution to journalArticle

Kelley, JL, Bullock, RM, Krochmal, MP, McLean, EW, Linn, JA, Durcan, MJ & Cooper, BR 1997, '6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents', Journal of Medicinal Chemistry, vol. 40, no. 20, pp. 3207-3216. https://doi.org/10.1021/jm960662s
Kelley, James L. ; Bullock, R Morris ; Krochmal, Mark P. ; McLean, Ed W. ; Linn, James A. ; Durcan, Micheal J. ; Cooper, Barrett R. / 6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents. In: Journal of Medicinal Chemistry. 1997 ; Vol. 40, No. 20. pp. 3207-3216.
@article{92235155d7a54f54bc4d576a64b22755,
title = "6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents",
abstract = "A series of 6-(alkylamino)-9-alkylpurines was synthesized and evaluated for the property of antagonizing the behavioral effects in animals of the dopamine agonist apomorphine. This model for identifying potential antipsychotic agents is based on the hypothesis that agents that antagonize apomorphine-induced aggressive behavior in rats and apomorphine-induced climbing in mice, but that do not block stereotyped behavior, could have an antipsychotic effect in humans without producing extrapyramidal side effects. The antiaggressive-behavior activity of lead compound 1 (6-(dimethylamino)- 9-(3-phenylalaninamidobenzyl)-9H-purine) was improved 48-fold with 6- (cyclopropylamino)-9-(cyclopropylmethyl)-2-(trifluoromethyl)-9H-purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterative sequence of structure-activity relationship studies that encompassed evaluation of the effects of structure variations at the purine 9-, 6-, and 2-positions. Potency was enhanced with a 9-cyclopropyl group, the duration of action was improved with the 6-(cyclopropylamino) substituent, potency was further enhanced with an N-formyl prodrug, and an agent with reduced cardiovascular effect emerged with the 2-trifluoromethyl purine 80. This potential antipsychotic agent was not developed further due to undesirable effects on the stomach.",
author = "Kelley, {James L.} and Bullock, {R Morris} and Krochmal, {Mark P.} and McLean, {Ed W.} and Linn, {James A.} and Durcan, {Micheal J.} and Cooper, {Barrett R.}",
year = "1997",
doi = "10.1021/jm960662s",
language = "English",
volume = "40",
pages = "3207--3216",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "20",

}

TY - JOUR

T1 - 6-(alkylamino)-9-alkylpurines. A new class of potential antipsychotic agents

AU - Kelley, James L.

AU - Bullock, R Morris

AU - Krochmal, Mark P.

AU - McLean, Ed W.

AU - Linn, James A.

AU - Durcan, Micheal J.

AU - Cooper, Barrett R.

PY - 1997

Y1 - 1997

N2 - A series of 6-(alkylamino)-9-alkylpurines was synthesized and evaluated for the property of antagonizing the behavioral effects in animals of the dopamine agonist apomorphine. This model for identifying potential antipsychotic agents is based on the hypothesis that agents that antagonize apomorphine-induced aggressive behavior in rats and apomorphine-induced climbing in mice, but that do not block stereotyped behavior, could have an antipsychotic effect in humans without producing extrapyramidal side effects. The antiaggressive-behavior activity of lead compound 1 (6-(dimethylamino)- 9-(3-phenylalaninamidobenzyl)-9H-purine) was improved 48-fold with 6- (cyclopropylamino)-9-(cyclopropylmethyl)-2-(trifluoromethyl)-9H-purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterative sequence of structure-activity relationship studies that encompassed evaluation of the effects of structure variations at the purine 9-, 6-, and 2-positions. Potency was enhanced with a 9-cyclopropyl group, the duration of action was improved with the 6-(cyclopropylamino) substituent, potency was further enhanced with an N-formyl prodrug, and an agent with reduced cardiovascular effect emerged with the 2-trifluoromethyl purine 80. This potential antipsychotic agent was not developed further due to undesirable effects on the stomach.

AB - A series of 6-(alkylamino)-9-alkylpurines was synthesized and evaluated for the property of antagonizing the behavioral effects in animals of the dopamine agonist apomorphine. This model for identifying potential antipsychotic agents is based on the hypothesis that agents that antagonize apomorphine-induced aggressive behavior in rats and apomorphine-induced climbing in mice, but that do not block stereotyped behavior, could have an antipsychotic effect in humans without producing extrapyramidal side effects. The antiaggressive-behavior activity of lead compound 1 (6-(dimethylamino)- 9-(3-phenylalaninamidobenzyl)-9H-purine) was improved 48-fold with 6- (cyclopropylamino)-9-(cyclopropylmethyl)-2-(trifluoromethyl)-9H-purine (80) (po ED50 of 2 mg/kg), which was obtained through an iterative sequence of structure-activity relationship studies that encompassed evaluation of the effects of structure variations at the purine 9-, 6-, and 2-positions. Potency was enhanced with a 9-cyclopropyl group, the duration of action was improved with the 6-(cyclopropylamino) substituent, potency was further enhanced with an N-formyl prodrug, and an agent with reduced cardiovascular effect emerged with the 2-trifluoromethyl purine 80. This potential antipsychotic agent was not developed further due to undesirable effects on the stomach.

UR - http://www.scopus.com/inward/record.url?scp=9844225050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844225050&partnerID=8YFLogxK

U2 - 10.1021/jm960662s

DO - 10.1021/jm960662s

M3 - Article

C2 - 9379440

AN - SCOPUS:9844225050

VL - 40

SP - 3207

EP - 3216

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 20

ER -